Masayuki Amagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masayuki Amagai has a total of 524 co-authors. Here are the top co-authors by number of shared publications:
- Akiharu Kubo
Division of Dermatology, Department of Internal Related Kobe University Graduate School of Medicine Kobe Japan
15 shared publications Jun Yamagami
Keio Univ, Dept Dermatol, Tokyo, Japan
15 shared publications- Hayato Takahashi
Department of Dermatology Keio University School of Medicine Tokyo Japan
13 shared publications - Takeshi Matsui
Tokyo University of Technology
10 shared publications - Yoshihiro Ito
Department of Dermatology Keio University School of Medicine Tokyo Japan
9 shared publications - Jun Yamagami
Department of Dermatology, Tokyo Women's Medical University, Tokyo, Japan
7 shared publications
Latest Publications
- 19 November 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (20) , 2070-2073
Revertant Autograft Replacement in Recessive Dystrophic Epidermolysis Bullosa
- 19 November 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (20) , 2070-2073
Revertant Autograft Replacement in Recessive Dystrophic Epidermolysis Bullosa
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9986
RNase-mediated defence and its association with SCCmec in Staphylococcus aureus
The rise of antibiotic resistance in Staphylococcus aureus is a major threat to global health. Resistance often emerges when bacteria acquire foreign DNA elements, such as the SCCmec cassette that makes strains resistant to nearly all β-lactam antibiotics. Yet, not all S. aureus lineages take up these elements equally, raising the question of what prevents some strains from becoming drug-resistant. Here we identify a previously unknown defence factor that explains this mystery in a common skin lineage (ST188), frequently isolated from patients with atopic dermatitis. Such defence factor is encoded by a gene, which we name sadR, that is present in methicillin-susceptible ST188 strains but absent from resistant counterparts. SadR exhibits RNase activity that provides anti-bacteriophage and anti-plasmid defence, thus acting as a barrier to the uptake of mobile genetic elements. Gene sadR is found in methicillin-susceptible strains in S. aureus lineages other than ST188, and is consistently located adjacent to rlmH, the canonical SCCmec integration site. Moreover, SadR homologues are widespread across staphylococci and other bacteria suggesting a previously unrecognised family of RNase-based defence systems.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9986
Open AccessRNase-mediated defence and its association with SCCmec in Staphylococcus aureus
The rise of antibiotic resistance in Staphylococcus aureus is a major threat to global health. Resistance often emerges when bacteria acquire foreign DNA elements, such as the SCCmec cassette that makes strains resistant to nearly all β-lactam antibiotics. Yet, not all S. aureus lineages take up these elements equally, raising the question of what prevents some strains from becoming drug-resistant. Here we identify a previously unknown defence factor that explains this mystery in a common skin lineage (ST188), frequently isolated from patients with atopic dermatitis. Such defence factor is encoded by a gene, which we name sadR, that is present in methicillin-susceptible ST188 strains but absent from resistant counterparts. SadR exhibits RNase activity that provides anti-bacteriophage and anti-plasmid defence, thus acting as a barrier to the uptake of mobile genetic elements. Gene sadR is found in methicillin-susceptible strains in S. aureus lineages other than ST188, and is consistently located adjacent to rlmH, the canonical SCCmec integration site. Moreover, SadR homologues are widespread across staphylococci and other bacteria suggesting a previously unrecognised family of RNase-based defence systems.
- 15 August 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (10) , 2687-2700
Regulatory T cells: From Foxp3 to tolerance-inducing therapies
- 15 August 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (10) , 2687-2700
Regulatory T cells: From Foxp3 to tolerance-inducing therapies
- 8 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2364-2366.e1
Not a new society, but a new way to connect: ISID-APAC as a new model for collaboration in investigative dermatology
- 8 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2364-2366.e1
Not a new society, but a new way to connect: ISID-APAC as a new model for collaboration in investigative dermatology
- 7 May 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1736-1739
Mechanistic insights into emerging therapeutic platforms: The 72nd annual Montagna Symposium on the Biology of Skin
- 7 May 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1736-1739
Mechanistic insights into emerging therapeutic platforms: The 72nd annual Montagna Symposium on the Biology of Skin
- Open Access
Interleukin‐22 and Interleukin‐18 as Potential Blood Biomarkers in Dupilumab‐Treated Atopic Dermatitis
- 16 February 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (4) , 547-562
Clinical progress of engineered cellular immunotherapies for autoimmunity
Cellular immunotherapies encompass a broad and rapidly developing group of treatments comprising expanded and/or genetically engineered immune cells, which use the specific properties of human immune cells to counteract human immune-mediated disease. Initially approved for cancers of the B cell lineage, a growing arsenal of cellular immunotherapies are being applied to autoimmune diseases, including chimeric antigen receptor (CAR) T cells, chimeric autoantibody receptor T cells, regulatory T cells and CAR-engineered innate immune cells. These approaches represent a major shift in the way scientists and physicians pursue the treatment of human disease compared to standard immunosuppressive therapies. Here, we review the clinical progress of engineered cellular immunotherapies for autoimmunity. We focus on how antigenic target, engineered cell type, CAR design and treatment regimens affect the therapeutic efficacy and safety of these treatments and how these emerging clinical data can inform future directions in the field.
- 16 February 2026
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (4) , 547-562
Clinical progress of engineered cellular immunotherapies for autoimmunity
Cellular immunotherapies encompass a broad and rapidly developing group of treatments comprising expanded and/or genetically engineered immune cells, which use the specific properties of human immune cells to counteract human immune-mediated disease. Initially approved for cancers of the B cell lineage, a growing arsenal of cellular immunotherapies are being applied to autoimmune diseases, including chimeric antigen receptor (CAR) T cells, chimeric autoantibody receptor T cells, regulatory T cells and CAR-engineered innate immune cells. These approaches represent a major shift in the way scientists and physicians pursue the treatment of human disease compared to standard immunosuppressive therapies. Here, we review the clinical progress of engineered cellular immunotherapies for autoimmunity. We focus on how antigenic target, engineered cell type, CAR design and treatment regimens affect the therapeutic efficacy and safety of these treatments and how these emerging clinical data can inform future directions in the field.
- Open Access
- 2 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1586-1595.e5
Microbial dysbiosis and foot odor in Nagashima-type palmoplantar keratosis: Improvement with topical benzoyl peroxide
- 2 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1586-1595.e5
Open AccessMicrobial dysbiosis and foot odor in Nagashima-type palmoplantar keratosis: Improvement with topical benzoyl peroxide
- Top Cited Papers
- 22 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (821) , eadq9913
Conversion of pathogenic T cells into functionally stabilized T reg cells for antigen-specific immunosuppression in pemphigus vulgaris
Antigen-specific immunotherapy represents one candidate strategy for treating autoimmune diseases such as pemphigus vulgaris, a skin autoimmune disorder mediated by anti–desmoglein 3 (Dsg3) autoantibodies. We developed a therapeutic strategy by which Dsg3-specific pathogenic autoreactive CD4 + T cells were converted in vitro into functionally stable Foxp3 + regulatory T (T reg ) cells, designated stable and functional induced T reg (S/F-iT reg ) cells. The conversion was achieved by pharmacological induction of Foxp3 and costimulation-dependent installation of T reg cell–specific epigenetic changes. In an animal model of pemphigus vulgaris, the Dsg3-specific S/F-iT reg cells expanded specifically in the skin-draining lymph nodes through recognition of endogenous Dsg3. They selectively inhibited Dsg3-specific T follicular helper cell and B cell proliferation and, consequently, anti-Dsg3 autoantibody formation, without affecting the total B cell population, thereby mitigating disease progression without inducing systemic immunosuppression. Human S/F-iT reg cells with similar functions could also be efficiently generated from peripheral blood T cells of patients with pemphigus vulgaris. This study demonstrates that pathogenic autoreactive T cells can be converted into disease-specific T reg cells retaining antigen specificity, enabling antigen- and disease-specific treatment of autoimmune disease.
- 22 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (821) , eadq9913
Top Cited PapersConversion of pathogenic T cells into functionally stabilized T reg cells for antigen-specific immunosuppression in pemphigus vulgaris
Antigen-specific immunotherapy represents one candidate strategy for treating autoimmune diseases such as pemphigus vulgaris, a skin autoimmune disorder mediated by anti–desmoglein 3 (Dsg3) autoantibodies. We developed a therapeutic strategy by which Dsg3-specific pathogenic autoreactive CD4 + T cells were converted in vitro into functionally stable Foxp3 + regulatory T (T reg ) cells, designated stable and functional induced T reg (S/F-iT reg ) cells. The conversion was achieved by pharmacological induction of Foxp3 and costimulation-dependent installation of T reg cell–specific epigenetic changes. In an animal model of pemphigus vulgaris, the Dsg3-specific S/F-iT reg cells expanded specifically in the skin-draining lymph nodes through recognition of endogenous Dsg3. They selectively inhibited Dsg3-specific T follicular helper cell and B cell proliferation and, consequently, anti-Dsg3 autoantibody formation, without affecting the total B cell population, thereby mitigating disease progression without inducing systemic immunosuppression. Human S/F-iT reg cells with similar functions could also be efficiently generated from peripheral blood T cells of patients with pemphigus vulgaris. This study demonstrates that pathogenic autoreactive T cells can be converted into disease-specific T reg cells retaining antigen specificity, enabling antigen- and disease-specific treatment of autoimmune disease.